Matthew L. Posard, Director at HALOZYME THERAPEUTICS, INC. (HALO), sold 30,000 shares at $56.12 ($1.7M) on 2022-12-06, disclosed to the SEC on 2022-12-06.
Open-market sale of $1.7M HALO by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $58.80 | 10,000 | $588K | 34.5% |
| 2 | $55.74 | 10,000 | $557K | 32.7% |
| 3 | $56.12 | 10,000 | $561K | 32.9% |
| Total | $56.89 avg | 30,000 | $1.7M | 100% |
| Filing → |
| HALO | SELL | 2024-08-14 | $2.3M | — | Filing → |
| HALO | SELL | 2024-06-13 | $1.0M | — | Filing → |
| NAUT | BUY | 2021-12-01 | $226K | — | Filing → |